Clinical Trials
14 trialsNCT01946204 2026-06-05
SPARTAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02257736 2026-06-05
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02489318 2026-06-05
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02531516 2026-06-05
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT03523442 2026-06-05
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT03767244 2026-06-05
PROTEUS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04108208 2026-06-05
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
Phase 4 Active not recruiting
NCT04325828 2026-06-05
YATAGARASU
Janssen Pharmaceutical K.K.
Phase 2 Active not recruiting
NCT04557059 2026-06-05
PRIMORDIUM
Janssen Pharmaceutica N.V., Belgium
Phase 3 Active not recruiting
NCT04662580 2026-06-05
ARX517
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05884398 2026-06-05
LIBERTAS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05901649 2026-06-05
ArtemisPRO
Janssen-Cilag Ltd.
Active not recruiting
NCT05367440 2026-06-01
PETRANHA
AstraZeneca
Phase 1/2 Active not recruiting
NCT04530552 2026-05-29
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
National Cancer Institute (NCI)
Phase 2 Active not recruiting